aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company (“aVenture”) is an independent research platform providing information and analysis about startups.
Certain metrics provided by aVenture may seek to assess the risks and opportunities associated with a company, fund, or its representatives (collectively “research”). aVenture seeks to provide this information with objectivity and fairness, and with diligence about its accuracy. Nonetheless, aVenture cannot provide assurance as to the accuracy of the information provided by our research. We strongly advise those using the research platform to seek multiple, independent sources for your research when making financial decisions.
Any links provided to other websites are offered as a matter of convenience and are not intended to imply that aVenture or its authors endorse, sponsor, promote, and/or are affiliated with the owners of or participants in those sites.
The aVenture platform also provides investment listings offered by independent investment advisers in the United States. aVenture is neither a registered investment adviser nor an exempt reporting adviser under the Investment Advisers Act of 1940, and no statements made by aVenture are intended to imply any financial instruments are under the counsel or advice of aVenture or its representatives.
Funds offered on the platform are generally managed by a private investment adviser that, unless stated otherwise, claims exemption from SEC or state registration. Investment funds presented on the platform are only available to investors who meet the requirements of the offering, and solicitations are not made outside those listed jurisdictions.
Additionally, each investment offered on the platform has qualifications for eligibility, including some offered only to Qualified Clients and/or Accredited Investors. Certain funds may be available to non-Qualified or Accredited investors, but only those who become personally known and identifiable to aVenture Investment Company staff, who have had an opportunity to assess the financial capacity and suitability for such an investment, and discuss its risks. Funds, when offered, are only offered following a review of a Private Placement Memorandum (PPM), subscription agreement, and other disclosures.
Investments in startups, venture capital, angel investments, private equity, real estate, stocks, and similar asset classes all involve risks, including: the risk of a decline in the value of your investments, including potentially large declines (suddenly and/or for long periods of time), the potential for illiquidity where part or all of a withdrawal request may not be honored on the date requested (even when a feature of the fund). These risks are heightened during periods of market duress.
Diversification has the possibility of reducing the magnitude of declines (either caused by market/economic factors, or by factors related to the individual company), but does not guarantee these risks have been fully or partially alleviated. Most importantly, past results are not an assurance of future outcomes. While most of these risks are shared and similarly held by other investment asset classes, we recommend investors only consider venture capital investments as part of a broader, diversified portfolio of stocks, bonds, and immediately accessible cash reserves.
From Startups | TechCrunch
By Christine Hall
March 26, 2024
One of the hardest things about being pregnant is learning what to eat for maximum digestive comfort and nutrition. Once the baby is born, the nutrition guessing game continues on which foods are ideal for postpartum and nursing.
Chiyo wants to be that support system by offering nutrition advice and meals in the form of a meal delivery service to women from fertility through postpartum as part of its holistic approach to fertility care. Chiyo offers digital guides and health coaching for its users and is also working to build what it considers the “first-of-its-kind” research database of nutrition for women’s health.
Irene Liu, co-founder and CEO, got the idea for Chiyo after seeing her mother send her aunt traditional Chinese medicine meals after her aunt had a baby. Liu was always interested in the concept of food as medicine, and wanted to pull from her background in nutritional science combined with Eastern food therapy to create stage-based and symptom-specific nutrition programs for other mothers.
“My family is Taiwanese, and I’ve always grown up with a more holistic medicine approach, and how you use food to prevent disease, heal and make you feel better — a more functional food way of thinking,” Liu told TechCrunch. “After seeing what postpartum care looks like in Asia and other more ancient cultures, I wondered why this doesn’t exist in the U.S. Why aren’t we using functional food in this way for a really important lifestyle if your body keeps changing?”
Liu started her career at Bain & Co., understanding the economics of food systems, and then worked for a nonprofit on the south side of Chicago, setting up local grocery routes. Combining an interest in food as medicine with a policy degree from Harvard and a business degree from Wharton gave Liu some food for thought — if you will — about how to build a local thriving economy through economic development initiatives so that a food system can support itself.
She met co-founder Jennifer Jolorte Doro, a clinical nutritionist and postpartum private chef. They initially launched a pilot program, a five-week postpartum meal delivery service to new mothers in New York City.
As Liu puts it, the pilot never ended. The company’s website was boosted organically on Google during that time, and the pair started getting thousands of pre-orders. “All of this was flying by the seat of our pants, just to ship the product,” Liu said.
So they founded Chiyo in 2020 and began shipping meals nationwide from a kitchen in Kearny, New Jersey. The co-founders liked the idea of a company that offered the actual meals, rather than something digital only, because selling a product would provide “richer data” around how people would use their offerings.
The company has served 100,000 meals since launching in 2021, and revenue grew 300% in the last 12 months amid a nationwide expansion, though Liu declined to specify what the actual revenue number was. In addition, Chiyo works with more than 100 women’s health practitioners.
The product roadmap is evolving, too, extending from the postpartum program to eventually serve the full women’s health journey. This includes a menstrual cycle fertility program that sends tonics and broths based on your menstrual cycle. Then on the postpartum side, the foods will change based on your estimated due date.
And unlike other meal service providers that want you to be customers for life, Chiyo’s goal is to get you off of its program. The average user is on the program for about four weeks. The 40-days postpartum program, which includes three meals per day, starts at $69 per day.
“We’ve become more prescriptive about the timing that impacts the outcomes on your body,” Liu said. “For example, we started with the first 40-days postpartum program. Then we launched framing and understanding of what’s happening in your body within the first six weeks of postpartum, and what’s really important. We’ve seen our customers increase from, for example, even two weeks for postpartum recovery.”
Now the company aims to build a digital platform for personalized customer self-guided content and nutrition programs. Eventually, users will be able to rate each solution’s efficacy and help contribute to the research database of nutrition for women’s health.
This is buoyed by a new investment of $3 million, led by early-stage investor Bread & Butter Ventures. Other participants in the round include Ingeborg, Union Heritage Ventures, Peterson Ventures, Detroit Venture Partners, Palette Ventures and The Helm.
The company has now raised a total of $3.4 million. Other backers include fashion blogger and designer Aimee Song, former CFO of the Momofuku restaurant chain Elizabeth Chrystal, Jing from Fly by Jing and Health-Ade co-founder Vanessa Dew.
The new funding also enables Chiyo to scale its distribution through clinics and its practitioner community and invest in additional food as medicine research.
“From all of that work, we are out to prove the ROI on investing in nutrition and healthcare cost savings so that eventually this program can be reimbursed and not have to be out-of-pocket,” Liu said. “We are also working with a number of clinics and hospital systems on how to be a nutrition plug-in. If their patient has any nutritional questions, or wants more nutritional support, it’s a co-branded entry point into our ecosystem.”
Have a juicy tip or lead about happenings in the venture world? Send tips to Christine Hall at [email protected] or via this Signal link. Anonymity requests will be respected.
View original article on techcrunch.com
Share:
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of Foresite Capital, announced that they incubated Xaira Therapeutics and funded the AI biotech with $1 billion. Other investors […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 25, 2024
Eric Schmidt-backed Augment, a GitHub Copilot rival, launches out of stealth with $252M
AI is supercharging coding — and developers are embracing it. In a recent StackOverflow poll, 44% of software engineers said that they use AI tools as part of their development processes now and 26% plan to soon. Gartner estimates that over half of organizations are currently piloting or have already deployed AI-driven coding assistants, and […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Radical thinks the time has come for solar-powered, high-altitude autonomous aircraft
Though many eyes are on space as orbit develops into a thriving business ecosystem, Radical is keeping things a little closer to the ground — but not too close. Its high-altitude, solar-powered aircraft aim to succeed where Facebook’s infamous Aquila failed by refining the tech and embracing more markets. It’s hard to believe that Facebook’s […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Don't miss our latest news and updates. Subscribe to the newsletter
More from Tech Crunch: